| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total operating expenses | 88,628 | 27,384 | 25,269 | 17,394 |
| Loss from operations | -88,628 | -27,384 | -25,269 | -17,394 |
| Other expense, net | 0 | 0 | 110 | - |
| Interest income, net | 5,395 | 1,666 | 1,899 | 1,859 |
| Total other income, net | 5,395 | 1,666 | 1,789 | 1,859 |
| Net loss from continuing operations before income tax expense | - | - | - | -15,535 |
| Net loss from continuing operations | -83,233 | -25,718 | -23,480 | -15,535 |
| (loss) income from discontinued operations (including loss on disposal of discontinued operations of zero and 1,799 during the three and nine months ended september 30, 2024, respectively), net of income taxes | 0 | 0 | - | -450 |
| Net loss | -83,233 | -25,718 | -23,480 | -15,985 |
| Unrealized loss on available-for-sale investments | -107 | - | - | - |
| Comprehensive loss | -83,340 | - | - | - |
| Basic net loss per common share (in dollars per share) | -3.1 | -1.65 | -1.66 | -2.45 |
| Diluted net loss per common share (in dollars per share) | -3.1 | -1.65 | -1.66 | -2.45 |
| Shares used to compute basic net earnings (loss) per common share (in shares) | 26,882,366 | 15,547,403 | 14,177,743 | 6,530,111 |
| Shares used to compute diluted net earnings (loss) per common share (in shares) | 26,882,366 | 15,547,403 | 14,177,743 | 6,530,111 |
Cidara Therapeutics, Inc. (CDTX)
Cidara Therapeutics, Inc. (CDTX)